Login
Super Investors EQT Fund Management S.a r.l.
EF

EQT Fund Management S.a r.l.

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$947M
Positions
6
Quarter ended
September 30, 2026
Filed
November 12, 2026

Reported portfolio value by quarter (11 quarters reported)

$1.86B —
Q2 22 Q1 23 Q3 25 Q2 26 Q3 26

$775M in Q2 2022 → $947M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
WH Waystar Hldg Corp 66.5% Unchanged 24,879,437 $630M
Pharvaris N V 11.5% Unchanged 3,424,609 $109M
Oculis Holding Ag 6.9% Unchanged 6,950,294 $64.9M
Agomab Therapeutics Nv 6.0% Unchanged 5,141,992 $57.1M
Evommune Inc 4.6% Unchanged 5,288,313 $43.7M
ET Electra Therapeutics Inc 4.5% New 3,795,281 $42.7M

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 12, 2026

Company Action Shares changed Value of change % of portfolio
ET Electra Therapeutics Inc New +3,795,281 +$42.7M 4.5%

Q2 2026

quarter ended June 30, 2026 · filed August 13, 2026

Company Action Shares changed Value of change % of portfolio
Oculis Holding Ag Added +1,050,000 +$14.6M 11.2%
Evommune Inc Added +358,680 +$4.77M 8.1%

Q1 2026

quarter ended March 31, 2026 · filed May 14, 2026

Company Action Shares changed Value of change % of portfolio
Agomab Therapeutics Nv New +5,141,992 +$53.9M 5.3%

Q4 2025

quarter ended December 31, 2025 · filed February 11, 2026

Company Action Shares changed Value of change % of portfolio
KG Kodiak Gas Svcs Inc Exited −19,762,573 −$731M —
Evommune Inc New +4,929,633 +$84.4M 7.6%

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
WH Waystar Hldg Corp New +24,879,437 +$943M 50.6%
KG Kodiak Gas Svcs Inc New +19,762,573 +$731M 39.2%
Oculis Holding Ag New +5,900,294 +$104M 5.6%
Pharvaris N V New +3,424,609 +$85.4M 4.6%
N None Exited +0 — —

Q3 2023

quarter ended September 30, 2023 · filed October 30, 2023

No position changes this quarter.

Q2 2023

quarter ended June 30, 2023 · filed August 09, 2023

No position changes this quarter.

Q1 2023

quarter ended March 31, 2023 · filed April 19, 2023

No position changes this quarter.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support